Durbin and Jazz coordinate early access for wakefulness medicine

Jazz will partner with Durbin to make Sunosi available to patients meeting defined criteria

Durbin has been appointed to design and implement a global early access program (EAP) on behalf of Jazz Pharmaceuticals for a medicine containing the active substance solriamfetol, known commercially as Sunosi.

The therapy is approved in the EU to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adults with narcolepsy (with or without cataplexy) or obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP).

Access will be provided in response to unsolicited requests from clinical specialists on a named-patient basis, in accordance with local regulations.

Jazz made Sunosi commercially available in Germany on 15 May 2020 and will pursue rolling commercial launches across the EU. Partnering with Jazz, Durbin will make Sunosi available in non-commercialised territories.

“At Jazz, we are committed to making our medicines available for those who need them,” said Samantha Pearce, Head of Europe & International, Jazz Pharmaceuticals. “Jazz and Durbin have a long-standing relationship and we’re looking forward to working with them to help enable people living with excessive daytime sleepiness as a result of OSA or narcolepsy have access to Sunosi through this program.”

Dan Piggott, managing director of Durbin, said: “We are pleased to be working in partnership once more with Jazz on a program that seeks to help people living with the effects of EDS related to OSA or narcolepsy. We have partnered with Jazz for over 10 years and this program is further confirmation of the value we have been able to deliver through such programs in that time.

Companies